Evidence map›Paper›PMID 42509256›Full record

ArticleLeukemia2026

Cohesin haploinsufficiency and inv(16) cooperate to reinforce Fli1 gene transcriptional programs during acute myeloid leukemia initiation and maintenance.

Alison E Meyer, Katelyn E Heimbruch, Kirthi Pulakanti, Cary Stelloh, Nataly Cruz-Rodriguez, Josiah Murray, Dandan Wang, Lisa Latzko, Sebastian Vosberg, Philipp A Greif and 4 more

Abstract read
In one paragraph

Article in Leukemia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Alison E Meyer *Versiti Blood Research Institute, Milwaukee, WI, USA.
Katelyn E Heimbruch *Pediatric Residency Program, Cincinnati Children's Hospital, Cincinnati, OH, USA.
Kirthi PulakantiVersiti Blood Research Institute, Milwaukee, WI, USA.ORCID http://orcid.org/0000-0003-1167-8493
Cary StellohVersiti Blood Research Institute, Milwaukee, WI, USA.
Nataly Cruz-RodriguezVersiti Blood Research Institute, Milwaukee, WI, USA.
Josiah MurrayDepartment of Cell Biology, Neurobiology, and Anatomy, Medical College of Wisconsin, Milwaukee, WI, USA.ORCID http://orcid.org/0000-0003-3651-6036
Dandan WangVersiti Blood Research Institute, Milwaukee, WI, USA.
Lisa LatzkoDepartment of Medicine III, University Hospital, LMU Munich, Munich, Germany.ORCID http://orcid.org/0009-0009-6799-7697
Sebastian VosbergDepartment of Medicine III, University Hospital, LMU Munich, Munich, Germany.ORCID http://orcid.org/0000-0002-8464-1483
Philipp A GreifDepartment of Medicine III, University Hospital, LMU Munich, Munich, Germany.
Lucio H CastillaDepartment of Molecular, Cell and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA, USA.ORCID http://orcid.org/0000-0002-7450-758X
John A PulikkanVersiti Blood Research Institute, Milwaukee, WI, USA.
Subramaniam MalarkannanVersiti Blood Research Institute, Milwaukee, WI, USA.
Sridhar RaoVersiti Blood Research Institute, Milwaukee, WI, USA. sridhar.rao@versiti.org.ORCID http://orcid.org/0000-0003-2688-9541

Funding

Sequencing Coordination and Data Analysis CoreP01HL149620 · NHLBI · UNIVERSITY OF ARIZONA · PI LIU, PENGYUAN · 2020 to 2024
$11.8M
Defining GATA4’s Molecular Function in Gastric Cell BiologyR01DK134064 · NIDDK · NORTH CAROLINA STATE UNIVERSITY RALEIGH · PI BATTLE, MICHELE A, RAO, SRIDHAR · 2022 to 2025
$2.1M
Cohesin Mutations in Acute Myelogenous LeukemiaR01CA204231 · NCI · VERSITI WISCONSIN, INC. · PI RAO, SRIDHAR · 2017 to 2021
$1.9M
GATA2-TGF beta-TAL1 pathway as a critical mediator of NK Cell developmentR01AI183571 · NIAID · MEDICAL COLLEGE OF WISCONSIN · PI BARBARA L. KEE, Subramaniam Malarkannan · 2025 to 2026
$1.5M
Cohesin Mutations in Core-Binding Factor Acute Myeloid LeukemiaF30CA236322 · NCI · VERSITI WISCONSIN, INC. · PI HEIMBRUCH, KATELYN E · 2019 to 2022
$200k
NCI NIH HHS F30 CA236322NCI NIH HHS R01 CA204231NHLBI NIH HHS P01 HL149620NIAID NIH HHS R01 AI183571NIDDK NIH HHS R01 DK134064U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) CA204231U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) CA236322U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) HL149620U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (National Institute of Diabetes & Digestive & Kidney Diseases) DK134064
6 · The paper itself

Abstract

Core binding factor (CBF) acute myeloid leukemias typically harbor the translocations t(8;21) or inv(16). As cohesin mutations are less commonly observed with inv(16) than with t(8;21), we hypothesized that they may negatively impact inv(16)-driven AML. Using a mouse model of inv(16) with haploinsufficiency of the cohesin subunit Smc3, we paradoxically found that inv(16); Smc3

Indexed as

Cell Cycle ProteinsChromosomal Proteins, Non-HistoneChromosome InversionGene Expression Regulation, LeukemicHaploinsufficiencyLeukemia, Myeloid, AcuteProto-Oncogene Protein c-fli-1Transcription, GeneticAnimalsChondroitin Sulfate ProteoglycansCohesinsHematopoietic Stem CellsMiceCell Cycle ProteinsChondroitin Sulfate ProteoglycansChromosomal Proteins, Non-HistoneCohesinsFli1 protein, mouseProto-Oncogene Protein c-fli-1SMC3 protein, mouse

Identifiers

PMID42509256
PMCPMC13612242

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.